Login Register Cart 0
Review Article

促性腺激素释放激素和GnRH受体:结构、功能和药物开发

卷 27, 期 36, 2020

页: [6136 - 6158] 页: 23

弟呕挨: 10.2174/0929867326666190712165444

价格: $65

conference banner
摘要

背景：促性腺激素释放激素(Gonadotropin-Releasing Hormone, GnRH)是人体性成熟和生殖周期调控的关键因子。GnRH通过激活促性腺激素释放激素受体(GnRHR)与垂体细胞相互作用。任何GnRH-GnRHR复合物的损伤/功能障碍都会导致各种癌症类型和疾病的发展。此外，GnRHR作为一个潜在的药物靶点已经导致了激动剂和拮抗剂分子的发展，在各种治疗方案中实现。这些药物的开发是基于从GnRH和GnRHR功能研究中获得的信息。 目的：本文旨在阐明GnRH和GnRH受体的多功能功能，并对不同激动剂、拮抗剂和非肽GnRH类似物的发展作一综述。 结论：从这些研究中获得的信息可以增强我们对GnRH-GnRHR多功能性质的理解，并为设计新的更有效的分子提供有价值的见解。

关键词: GnRH

« Previous Next »
[1]
Schally, A.V.; Arimura, A.; Kastin, A.J.; Matsuo, H.; Baba, Y.; Redding, T.W.; Nair, R.M.; Debeljuk, L.; White, W.F. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science, 1971, 173(4001), 1036-1038.
[http://dx.doi.org/10.1126/science.173.4001.1036] [PMID: 4938639]
[2]
Kaiser, U.B.; Conn, P.M.; Chin, W.W. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr. Rev., 1997, 18(1), 46-70.
[http://dx.doi.org/10.1210/er.18.1.46] [PMID: 9034786]
[3]
Meysing, A.U.; Kanasaki, H.; Bedecarrats, G.Y.; Acierno, J.S., Jr; Conn, P.M.; Martin, K.A.; Seminara, S.B.; Hall, J.E.; Crowley, W.F., Jr; Kaiser, U.B. GNRHR mutations in a woman with idiopathic hypogonadotropic hypogonadism highlight the differential sensitivity of luteinizing hormone and follicle-stimulating hormone to gonadotropin-releasing hormone. J. Clin. Endocrinol. Metab., 2004, 89(7), 3189-3198.
[http://dx.doi.org/10.1210/jc.2003-031808] [PMID: 15240592]
[4]
Baba, Y.; Matsuo, H.; Schally, A.V. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochem. Biophys. Res. Commun., 1971, 44(2), 459-463.
[http://dx.doi.org/10.1016/0006-291X(71)90623-1] [PMID: 4946067]
[5]
Ferris, H.A.; Shupnik, M.A. Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GNRH1. Biol. Reprod., 2006, 74(6), 993-998.
[http://dx.doi.org/10.1095/biolreprod.105.049049] [PMID: 16481592]
[6]
Czieselsky, K.; Prescott, M.; Porteous, R.; Campos, P.; Clarkson, J.; Steyn, F.J.; Campbell, R.E.; Herbison, A.E. Pulse and surge profiles of luteinizing hormone secretion in the mouse. Endocrinology, 2016, 157(12), 4794-4802.
[http://dx.doi.org/10.1210/en.2016-1351] [PMID: 27715255]
[7]
Maggi, R.; Cariboni, A.M.; Marelli, M.M.; Moretti, R.M.; Andrè, V.; Marzagalli, M.; Limonta, P. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum. Reprod. Update, 2016, 22(3), 358-381.
[http://dx.doi.org/10.1093/humupd/dmv059] [PMID: 26715597]
[8]
Joseph, N.T.; Morgan, K.; Sellar, R.; McBride, D.; Millar, R.P.; Dunn, I.C. The chicken type III GnRH receptor homologue is predominantly expressed in the pituitary and exhibits similar ligand selectivity to the type I receptor. J. Endocrinol., 2009, 202(1), 179-190.
[http://dx.doi.org/10.1677/JOE-08-0544] [PMID: 19380456]
[9]
Troskie, B.; Illing, N.; Rumbak, E.; Sun, Y.M.; Hapgood, J.; Sealfon, S.; Conklin, D.; Millar, R. Identification of three putative GnRH receptor subtypes in vertebrates. Gen. Comp. Endocrinol., 1998, 112(3), 296-302.
[http://dx.doi.org/10.1006/gcen.1998.7156] [PMID: 9843635]
[10]
True, C.; Takahashi, D.; Kirigiti, M.; Lindsley, S.R.; Moctezuma, C.; Arik, A.; Smith, M.S.; Kievit, P.; Grove, K.L. Arcuate nucleus neuropeptide coexpression and connections to gonadotrophin-releasing hormone neurones in the female rhesus macaque. J. Neuroendocrinol., 2017, 29(6), 29.
[http://dx.doi.org/10.1111/jne.12491] [PMID: 28561903]
[11]
Glanowska, K.M.; Burger, L.L.; Moenter, S.M. Development of gonadotropin-releasing hormone secretion and pituitary response. J. Neurosci., 2014, 34(45), 15060-15069.
[http://dx.doi.org/10.1523/JNEUROSCI.2200-14.2014] [PMID: 25378170]
[12]
Desaulniers, A.T.; Cederberg, R.A.; Mills, G.A.; Lents, C.A.; White, B.R. Production of a gonadotropin-releasing hormone 2 receptor knockdown (GNRHR2 KD) swine line. Transgenic Res., 2017, 26(4), 567-575.
[http://dx.doi.org/10.1007/s11248-017-0023-4] [PMID: 28534229]
[13]
Lents, C.A.; Thorson, J.F.; Desaulniers, A.T.; White, B.R. RFamide-related peptide 3 and gonadotropin-releasing hormone-II are autocrine-paracrine regulators of testicular function in the boar. Mol. Reprod. Dev., 2017, 84(9), 994-1003.
[http://dx.doi.org/10.1002/mrd.22830] [PMID: 28475264]
[14]
Ray, D.; Han, Y.; Franchitto, A.; DeMorrow, S.; Meng, F.; Venter, J.; McMillin, M.; Kennedy, L.; Francis, H.; Onori, P.; Mancinelli, R.; Gaudio, E.; Alpini, G.; Glaser, S.S. Gonadotropin-releasing hormone stimulates biliary proliferation by paracrine/autocrine mechanisms. Am. J. Pathol., 2015, 185(4), 1061-1072.
[http://dx.doi.org/10.1016/j.ajpath.2014.12.004] [PMID: 25794706]
[15]
Wen, S.; Götze, I.N.; Mai, O.; Schauer, C.; Leinders-Zufall, T.; Boehm, U. Genetic identification of GnRH receptor neurons: a new model for studying neural circuits underlying reproductive physiology in the mouse brain. Endocrinology, 2011, 152(4), 1515-1526.
[http://dx.doi.org/10.1210/en.2010-1208] [PMID: 21303944]
[16]
Schneider, J.S.; Rissman, E.F. Gonadotropin-releasing hormone II: a multi-purpose neuropeptide. Integr. Comp. Biol., 2008, 48(5), 588-595.
[http://dx.doi.org/10.1093/icb/icn018] [PMID: 21669818]
[17]
Mohamed, J.S.; Khan, I.A. Molecular cloning and differential expression of three GnRH mRNAs in discrete brain areas and lymphocytes in red drum. J. Endocrinol., 2006, 188(3), 407-416.
[http://dx.doi.org/10.1677/joe.1.06423] [PMID: 16522721]
[18]
Kuo, M.W.; Lou, S.W.; Postlethwait, J.; Chung, B.C. Chromosomal organization, evolutionary relationship, and expression of zebrafish GnRH family members. J. Biomed. Sci., 2005, 12(4), 629-639.
[http://dx.doi.org/10.1007/s11373-005-7457-z] [PMID: 16132106]
[19]
Morgan, K.; Millar, R.P. Evolution of GnRH ligand precursors and GnRH receptors in protochordate and vertebrate species. Gen. Comp. Endocrinol., 2004, 139(3), 191-197.
[http://dx.doi.org/10.1016/j.ygcen.2004.09.015] [PMID: 15560865]
[20]
López de Maturana, R.; Pawson, A.J.; Lu, Z.L.; Davidson, L.; Maudsley, S.; Morgan, K.; Langdon, S.P.; Millar, R.P. Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling. Mol. Endocrinol., 2008, 22(7), 1711-1722.
[http://dx.doi.org/10.1210/me.2006-0537] [PMID: 18467526]
[21]
Gründker, C.; Schlotawa, L.; Viereck, V.; Eicke, N.; Horst, A.; Kairies, B.; Emons, G. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur. J. Endocrinol., 2004, 151(1), 141-149.
[http://dx.doi.org/10.1530/eje.0.1510141] [PMID: 15248835]
[22]
Illing, N.; Troskie, B.E.; Nahorniak, C.S.; Hapgood, J.P.; Peter, R.E.; Millar, R.P. Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (Carassius auratus). Proc. Natl. Acad. Sci. USA, 1999, 96(5), 2526-2531.
[http://dx.doi.org/10.1073/pnas.96.5.2526] [PMID: 10051676]
[23]
Coccia, M.E.; Comparetto, C.; Bracco, G.L.; Scarselli, G. GnRH antagonists. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 115(Suppl. 1), S44-S56.
[http://dx.doi.org/10.1016/j.ejogrb.2004.01.033] [PMID: 15196716]
[24]
Varasteh Moradi, S.; Varamini, P.; Steyn, F.; Toth, I. In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. Int. J. Pharm., 2015, 495(1), 106-111.
[http://dx.doi.org/10.1016/j.ijpharm.2015.08.095] [PMID: 26325323]
[25]
Baldwin, E.L.; Wegorzewska, I.N.; Flora, M.; Wu, T.J. Regulation of type II luteinizing hormone-releasing hormone (LHRH-II) gene expression by the processed peptide of LHRH-I, LHRH-(1-5) in endometrial cells. Exp. Biol. Med. (Maywood), 2007, 232(1), 146-155.
[PMID: 17202595]
[26]
Walters, K.; Chin, Y.P.; Wu, T.J. A processed metabolite of luteinizing hormone-releasing hormone has proliferative effects in endometrial cells. Am. J. Obstet. Gynecol., 2007, 196(1), 33.e1-e5.
[http://dx.doi.org/10.1016/j.ajog.2006.07.054]] [PMID: 172400223]
[27]
Hannan, M.A.; Kawate, N.; Fukami, Y.; Weerakoon, W.W.; Büllesbach, E.E.; Inaba, T.; Tamada, H. Effects of long-acting GnRH antagonist, degarelix acetate, on plasma insulin-like peptide 3, testosterone and luteinizing hormone concentrations, and scrotal circumference in male goats. Theriogenology, 2017, 88, 228-235.
[http://dx.doi.org/10.1016/j.theriogenology.2016.09.032] [PMID: 27793455]
[28]
Salciccia, S.; Gentilucci, A.; Cattarino, S.; Sciarra, A. GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results. Urologia, 2016, 83(4), 173-178.
[http://dx.doi.org/10.5301/uro.5000194] [PMID: 27768220]
[29]
Lu, Z.L.; Coetsee, M.; White, C.D.; Millar, R.P. Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. J. Biol. Chem., 2007, 282(24), 17921-17929.
[http://dx.doi.org/10.1074/jbc.M610413200] [PMID: 17452338]
[30]
Wu, T.J.; Mani, S.K.; Glucksman, M.J.; Roberts, J.L. Stimulation of luteinizing hormone-releasing hormone (LHRH) gene expression in GT1-7 cells by its metabolite, LHRH-(1-5). Endocrinology, 2005, 146(1), 280-286.
[http://dx.doi.org/10.1210/en.2004-0560] [PMID: 15486221]
[31]
Moradi, S.V.; Varamini, P.; Toth, I. Evaluation of the biological properties and the enzymatic stability of glycosylated luteinizing hormone-releasing hormone analogs. AAPS J., 2015, 17(5), 1135-1143.
[http://dx.doi.org/10.1208/s12248-015-9769-x] [PMID: 25956382]
[32]
Wu, T.J.; Pierotti, A.R.; Jakubowski, M.; Sheward, W.J.; Glucksman, M.J.; Smith, A.I.; King, J.C.; Fink, G.; Roberts, J.L. Endopeptidase EC 3.4.24.15 presence in the rat median eminence and hypophysial portal blood and its modulation of the luteinizing hormone surge. J. Neuroendocrinol., 1997, 9(11), 813-822.
[http://dx.doi.org/10.1046/j.1365-2826.1997.00637.x] [PMID: 9419832]
[33]
Tena-Sempere, M. Hypothalamic KiSS-1: the missing link in gonadotropin feedback control? Endocrinology, 2005, 146(9), 3683-3685.
[http://dx.doi.org/10.1210/en.2005-0652] [PMID: 16105827]
[34]
Beneduzzi, D.; Trarbach, E.B.; Min, L.; Jorge, A.A.; Garmes, H.M.; Renk, A.C.; Fichna, M.; Fichna, P.; Arantes, K.A.; Costa, E.M.; Zhang, A.; Adeola, O.; Wen, J.; Carroll, R.S.; Mendonca, B.B.; Kaiser, U.B.; Latronico, A.C.; Silveira, L.F. Role of gonadotropin-releasing hormone receptor mutations in patients with a wide spectrum of pubertal delay. Fertil. Steril., 2014, 102(3), 838-846.e2.
[http://dx.doi.org/10.1016/j.fertnstert.2014.05.044] [PMID: 25016926]
[35]
Ciccone, N.A.; Xu, S.; Lacza, C.T.; Carroll, R.S.; Kaiser, U.B. Frequency-dependent regulation of follicle-stimulating hormone beta by pulsatile gonadotropin-releasing hormone is mediated by functional antagonism of bZIP transcription factors. Mol. Cell. Biol., 2010, 30(4), 1028-1040.
[http://dx.doi.org/10.1128/MCB.00848-09] [PMID: 20008557]
[36]
Krakauer, D.C.; Page, K.M.; Sealfon, S. Module dynamics of the GnRH signal transduction network. J. Theor. Biol., 2002, 218(4), 457-470.
[http://dx.doi.org/10.1016/S0022-5193(02)93092-4] [PMID: 12384049]
[37]
Finch, A.R.; Caunt, C.J.; Armstrong, S.P.; McArdle, C.A. Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists. Mol. Endocrinol., 2010, 24(2), 423-435.
[http://dx.doi.org/10.1210/me.2009-0343] [PMID: 20009083]
[38]
Karakoula, A.; Tovey, S.C.; Brighton, P.J.; Willars, G.B. Lack of receptor-selective effects of either RGS2, RGS3 or RGS4 on muscarinic M3- and gonadotropin-releasing hormone receptor-mediated signalling through G alpha q/11. Eur. J. Pharmacol., 2008, 587(1-3), 16-24.
[http://dx.doi.org/10.1016/j.ejphar.2008.03.047] [PMID: 18457830]
[39]
Wurmbach, E.; Yuen, T.; Ebersole, B.J.; Sealfon, S.C. Gonadotropin-releasing hormone receptor-coupled gene network organization. J. Biol. Chem., 2001, 276(50), 47195-47201.
[http://dx.doi.org/10.1074/jbc.M108716200] [PMID: 11581274]
[40]
Wojcikiewicz, R.J.; Xu, Q.; Webster, J.M.; Alzayady, K.; Gao, C. Ubiquitination and proteasomal degradation of endogenous and exogenous inositol 1,4,5-trisphosphate receptors in alpha T3-1 anterior pituitary cells. J. Biol. Chem., 2003, 278(2), 940-947.
[http://dx.doi.org/10.1074/jbc.M206607200] [PMID: 12421829]
[41]
Zerani, M.; Parillo, F.; Brecchia, G.; Guelfi, G.; Dall’Aglio, C.; Lilli, L.; Maranesi, M.; Gobbetti, A.; Boiti, C. Expression of type I GNRH receptor and in vivo and in vitro GNRH-I effects in corpora lutea of pseudopregnant rabbits. J. Endocrinol., 2010, 207(3), 289-300.
[http://dx.doi.org/10.1677/JOE-10-0109] [PMID: 20880984]
[42]
Chakrabarti, N.; Subbarao, T.; Sengupta, A.; Xu, F.; Stouffer, R.L.; Sridaran, R. Expression of mRNA and proteins for GnRH I and II and their receptors in primate corpus luteum during menstrual cycle. Mol. Reprod. Dev., 2008, 75(10), 1567-1577.
[http://dx.doi.org/10.1002/mrd.20898] [PMID: 18363198]
[43]
Larco, D.O.; Cho-Clark, M.; Mani, S.K.; Wu, T.J. The metabolite GnRH-(1-5) inhibits the migration of immortalized GnRH neurons. Endocrinology, 2013, 154(2), 783-795.
[http://dx.doi.org/10.1210/en.2012-1746] [PMID: 23321696]
[44]
Cho-Clark, M.; Larco, D.O.; Zahn, B.R.; Mani, S.K.; Wu, T.J. GnRH-(1-5) activates matrix metallopeptidase-9 to release epidermal growth factor and promote cellular invasion. Mol. Cell. Endocrinol., 2015, 415, 114-125.
[http://dx.doi.org/10.1016/j.mce.2015.08.010] [PMID: 26277400]
[45]
Larco, D.O.; Semsarzadeh, N.N.; Cho-Clark, M.; Mani, S.K.; Wu, T.J. The novel actions of the metabolite GnRH-(1-5) are mediated by a G protein-coupled receptor. Front. Endocrinol. (Lausanne), 2013, 4, 83.
[http://dx.doi.org/10.3389/fendo.2013.00083] [PMID: 23847594]
[46]
Larco, D.O.; Williams, M.; Schmidt, L.; Sabel, N.; Lange, J.; Woller, M.J.; Wu, T.J. Autoshortloop feedback regulation of pulsatile gonadotropin-releasing hormone (GnRH) secretion by its metabolite, GnRH-(1-5). Endocrine, 2015, 49(2), 470-478.
[http://dx.doi.org/10.1007/s12020-014-0492-7] [PMID: 25516463]
[47]
Tsutsumi, M.; Zhou, W.; Millar, R.P.; Mellon, P.L.; Roberts, J.L.; Flanagan, C.A.; Dong, K.; Gillo, B.; Sealfon, S.C. Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Mol. Endocrinol., 1992, 6(7), 1163-1169.
[PMID: 1324422]
[48]
Perrin, M.H.; Bilezikjian, L.M.; Hoeger, C.; Donaldson, C.J.; Rivier, J.; Haas, Y.; Vale, W.W. Molecular and functional characterization of GnRH receptors cloned from rat pituitary and a mouse pituitary tumor cell line. Biochem. Biophys. Res. Commun., 1993, 191(3), 1139-1144.
[http://dx.doi.org/10.1006/bbrc.1993.1335] [PMID: 7916600]
[49]
Chi, L.; Zhou, W.; Prikhozhan, A.; Flanagan, C.; Davidson, J.S.; Golembo, M.; Illing, N.; Millar, R.P.; Sealfon, S.C. Cloning and characterization of the human GnRH receptor. Mol. Cell. Endocrinol., 1993, 91(1-2), R1-R6.
[http://dx.doi.org/10.1016/0303-7207(93)90278-R] [PMID: 8386108]
[50]
Illing, N.; Jacobs, G.F.; Becker, I.I.; Flanagan, C.A.; Davidson, J.S.; Eales, A.; Zhou, W.; Sealfon, S.C.; Millar, R.P. Comparative sequence analysis and functional characterization of the cloned sheep gonadotropin-releasing hormone receptor reveal differences in primary structure and ligand specificity among mammalian receptors. Biochem. Biophys. Res. Commun., 1993, 196(2), 745-751.
[http://dx.doi.org/10.1006/bbrc.1993.2312] [PMID: 7694577]
[51]
Weesner, G.D.; Matteri, R.L. Rapid communication: nucleotide sequence of luteinizing hormone-releasing hormone (LHRH) receptor cDNA in the pig pituitary. J. Anim. Sci., 1994, 72(7), 1911.
[http://dx.doi.org/10.2527/1994.7271911x] [PMID: 7928774]
[52]
Tensen, C.; Okuzawa, K.; Blomenröhr, M.; Rebers, F.; Leurs, R.; Bogerd, J.; Schulz, R.; Goos, H. Distinct efficacies for two endogenous ligands on a single cognate gonadoliberin receptor. Eur. J. Biochem., 1997, 243(1-2), 134-140.
[http://dx.doi.org/10.1111/j.1432-1033.1997.0134a.x] [PMID: 9030732]
[53]
Wang, L.; Bogerd, J.; Choi, H.S.; Seong, J.Y.; Soh, J.M.; Chun, S.Y.; Blomenröhr, M.; Troskie, B.E.; Millar, R.P.; Yu, W.H.; McCann, S.M.; Kwon, H.B. Three distinct types of GnRH receptor characterized in the bullfrog. Proc. Natl. Acad. Sci. USA, 2001, 98(1), 361-366.
[http://dx.doi.org/10.1073/pnas.98.1.361] [PMID: 11120886]
[54]
Sun, Y.M.; Flanagan, C.A.; Illing, N.; Ott, T.R.; Sellar, R.; Fromme, B.J.; Hapgood, J.; Sharp, P.; Sealfon, S.C.; Millar, R.P. A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists. Identification of D-Lys(6) in the ligand and extracellular loop two of the receptor as determinants. J. Biol. Chem., 2001, 276(11), 7754-7761.
[http://dx.doi.org/10.1074/jbc.M009020200] [PMID: 11112780]
[55]
Millar, R.P.; Lu, Z.L.; Pawson, A.J.; Flanagan, C.A.; Morgan, K.; Maudsley, S.R. Gonadotropin-releasing hormone receptors. Endocr. Rev., 2004, 25(2), 235-275.
[http://dx.doi.org/10.1210/er.2003-0002] [PMID: 15082521]
[56]
Sefideh, F.A.; Moon, M.J.; Yun, S.; Hong, S.I.; Hwang, J.I.; Seong, J.Y. Local duplication of gonadotropin-releasing hormone (GnRH) receptor before two rounds of whole genome duplication and origin of the mammalian GnRH receptor. PLoS One, 2014, 9(2),e87901.
[http://dx.doi.org/10.1371/journal.pone.0087901] [PMID: 24498396]
[57]
Ferguson, S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev., 2001, 53(1), 1-24.
[PMID: 11171937]
[58]
Isberg, V.; Mordalski, S.; Munk, C.; Rataj, K.; Harpsøe, K.; Hauser, A.S.; Vroling, B.; Bojarski, A.J.; Vriend, G.; Gloriam, D.E. GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res., 2016, 44(D1), D356-D364.
[http://dx.doi.org/10.1093/nar/gkv1178] [PMID: 26582914]
[59]
Neill, J.D.; Musgrove, L.C.; Duck, L.W. Newly recognized GnRH receptors: function and relative role. Trends Endocrinol. Metab., 2004, 15(8), 383-392.
[http://dx.doi.org/10.1016/j.tem.2004.08.005] [PMID: 15380810]
[60]
Millar, R.P. GnRH II and type II GnRH receptors. Trends Endocrinol. Metab., 2003, 14(1), 35-43.
[http://dx.doi.org/10.1016/S1043-2760(02)00016-4] [PMID: 12475610]
[61]
Morgan, K.; Conklin, D.; Pawson, A.J.; Sellar, R.; Ott, T.R.; Millar, R.P. A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology, 2003, 144(2), 423-436.
[http://dx.doi.org/10.1210/en.2002-220622] [PMID: 12538601]
[62]
Montagnani Marelli, M.; Manea, M.; Moretti, R.M.; Marzagalli, M.; Limonta, P. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. Int. J. Oncol., 2015, 46(1), 243-253.
[http://dx.doi.org/10.3892/ijo.2014.2730] [PMID: 25351635]
[63]
Wu, H.M.; Huang, H.Y.; Lee, C.L.; Soong, Y.K.; Leung, P.C.; Wang, H.S. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy. Biol. Reprod., 2015, 92(4), 98.
[http://dx.doi.org/10.1095/biolreprod.114.127324] [PMID: 25761596]
[64]
Forfar, R.; Lu, Z.L. Role of the transmembrane domain 4/extracellular loop 2 junction of the human gonadotropin-releasing hormone receptor in ligand binding and receptor conformational selection. J. Biol. Chem., 2011, 286(40), 34617-34626.
[http://dx.doi.org/10.1074/jbc.M111.240341] [PMID: 21832286]
[65]
Pawson, A.J.; Maudsley, S.; Morgan, K.; Davidson, L.; Naor, Z.; Millar, R.P. Inhibition of human type I gonadotropin-releasing hormone receptor (GnRHR) function by expression of a human type II GnRHR gene fragment. Endocrinology, 2005, 146(6), 2639-2649.
[http://dx.doi.org/10.1210/en.2005-0133] [PMID: 15761034]
[66]
Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science, 2000, 289(5480), 739-745.
[http://dx.doi.org/10.1126/science.289.5480.739] [PMID: 10926528]
[67]
Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28(1), 235-242.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[68]
Isberg, V.; de Graaf, C.; Bortolato, A.; Cherezov, V.; Katritch, V.; Marshall, F.H.; Mordalski, S.; Pin, J.P.; Stevens, R.C.; Vriend, G.; Gloriam, D.E. Generic GPCR residue numbers - aligning topology maps while minding the gaps. Trends Pharmacol. Sci., 2015, 36(1), 22-31.
[http://dx.doi.org/10.1016/j.tips.2014.11.001] [PMID: 25541108]
[69]
Cvicek, V.; Goddard, W.A., III; Abrol, R. Structure-based sequence alignment of the transmembrane domains of all human gpcrs: phylogenetic, structural and functional implications. PLOS Comput. Biol., 2016, 12(3),e1004805.
[http://dx.doi.org/10.1371/journal.pcbi.1004805] [PMID: 27028541]
[70]
DeVree, B.T.; Mahoney, J.P.; Vélez-Ruiz, G.A.; Rasmussen, S.G.; Kuszak, A.J.; Edwald, E.; Fung, J.J.; Manglik, A.; Masureel, M.; Du, Y.; Matt, R.A.; Pardon, E.; Steyaert, J.; Kobilka, B.K.; Sunahara, R.K. Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature, 2016, 535(7610), 182-186.
[http://dx.doi.org/10.1038/nature18324] [PMID: 27362234]
[71]
Tzoupis, H.; Nteli, A.; Platts, J.; Mantzourani, E.; Tselios, T. Refinement of the gonadotropin releasing hormone receptor I homology model by applying molecular dynamics. J. Mol. Graph. Model., 2019, 89, 147-155.
[http://dx.doi.org/10.1016/j.jmgm.2019.03.009] [PMID: 30889428]
[72]
Awara, W.M.; Guo, C.H.; Conn, P.M. Effects of Asn318 and Asp87Asn318 mutations on signal transduction by the gonadotropin-releasing hormone receptor and receptor regulation. Endocrinology, 1996, 137(2), 655-662.
[http://dx.doi.org/10.1210/endo.137.2.8593815] [PMID: 8593815]
[73]
Flanagan, C.A.; Zhou, W.; Chi, L.; Yuen, T.; Rodic, V.; Robertson, D.; Johnson, M.; Holland, P.; Millar, R.P.; Weinstein, H.; Mitchell, R.; Sealfon, S.C. The functional microdomain in transmembrane helices 2 and 7 regulates expression, activation, and coupling pathways of the gonadotropin-releasing hormone receptor. J. Biol. Chem., 1999, 274(41), 28880-28886.
[http://dx.doi.org/10.1074/jbc.274.41.28880] [PMID: 10506131]
[74]
Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E.M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. USA, 2002, 99(9), 5982-5987.
[http://dx.doi.org/10.1073/pnas.082666399] [PMID: 11972040]
[75]
Murakami, M.; Kouyama, T. Crystallographic analysis of the primary photochemical reaction of squid rhodopsin. J. Mol. Biol., 2011, 413(3), 615-627.
[http://dx.doi.org/10.1016/j.jmb.2011.08.044] [PMID: 21906602]
[76]
Blomenröhr, M.; ter Laak, T.; Kühne, R.; Beyermann, M.; Hund, E.; Bogerd, J.; Leurs, R. Chimaeric gonadotropin-releasing hormone (GnRH) peptides with improved affinity for the catfish (Clarias gariepinus) GnRH receptor. Biochem. J., 2002, 361(Pt 3), 515-523.
[http://dx.doi.org/10.1042/bj3610515] [PMID: 11802781]
[77]
Coetsee, M.; Millar, R.P.; Flanagan, C.A.; Lu, Z.L. Identification of Tyr(290(6.58)) of the human gonadotropin-releasing hormone (GnRH) receptor as a contact residue for both GnRH I and GnRH II: importance for high-affinity binding and receptor activation. Biochemistry, 2008, 47(39), 10305-10313.
[http://dx.doi.org/10.1021/bi800911z] [PMID: 18771291]
[78]
Stewart, A.J.; Sellar, R.; Wilson, D.J.; Millar, R.P.; Lu, Z.L. Identification of a novel ligand binding residue Arg38(1.35) in the human gonadotropin-releasing hormone receptor. Mol. Pharmacol., 2008, 73(1), 75-81.
[http://dx.doi.org/10.1124/mol.107.040816] [PMID: 17942747]
[79]
Strader, C.D.; Fong, T.M.; Tota, M.R.; Underwood, D.; Dixon, R.A. Structure and function of G protein-coupled receptors. Annu. Rev. Biochem., 1994, 63, 101-132.
[http://dx.doi.org/10.1146/annurev.bi.63.070194.000533] [PMID: 7979235]
[80]
Costa, E.M.; Bedecarrats, G.Y.; Mendonca, B.B.; Arnhold, I.J.; Kaiser, U.B.; Latronico, A.C. Two novel mutations in the gonadotropin-releasing hormone receptor gene in Brazilian patients with hypogonadotropic hypogonadism and normal olfaction. J. Clin. Endocrinol. Metab., 2001, 86(6), 2680-2686.
[http://dx.doi.org/10.1210/jc.86.6.2680] [PMID: 11397871]
[81]
Bédécarrats, G.Y.; Linher, K.D.; Janovick, J.A.; Beranova, M.; Kada, F.; Seminara, S.B.; Michael Conn, P.; Kaiser, U.B. Four naturally occurring mutations in the human GnRH receptor affect ligand binding and receptor function. Mol. Cell. Endocrinol., 2003, 205(1-2), 51-64.
[http://dx.doi.org/10.1016/S0303-7207(03)00201-6] [PMID: 12890567]
[82]
Tello, J.A.; Newton, C.L.; Bouligand, J.; Guiochon-Mantel, A.; Millar, R.P.; Young, J. Congenital hypogonadotropic hypogonadism due to GnRH receptor mutations in three brothers reveal sites affecting conformation and coupling. PLoS One, 2012, 7(6),e38456.
[http://dx.doi.org/10.1371/journal.pone.0038456] [PMID: 22679506]
[83]
Manilall, A.; Stander, B.A.; Madziva, M.T.; Millar, R.P.; Flanagan, C.A. Glu(2.53(90)) of the GnRH receptor is part of the conserved G protein-coupled receptor structure and does not form a salt-bridge with Lys(3.32(121)). Mol. Cell. Endocrinol., 2019, 481, 53-61.
[http://dx.doi.org/10.1016/j.mce.2018.11.009] [PMID: 30476558]
[84]
Flanagan, C.A.; Rodic, V.; Konvicka, K.; Yuen, T.; Chi, L.; Rivier, J.E.; Millar, R.P.; Weinstein, H.; Sealfon, S.C. Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction. Biochemistry, 2000, 39(28), 8133-8141.
[http://dx.doi.org/10.1021/bi000085g] [PMID: 10889019]
[85]
Hoffmann, S.H.; ter Laak, T.; Kühne, R.; Reiländer, H.; Beckers, T. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol. Endocrinol., 2000, 14(7), 1099-1115.
[http://dx.doi.org/10.1210/mend.14.7.0483] [PMID: 10894158]
[86]
Davidson, J.S.; Flanagan, C.A.; Zhou, W.; Becker, I.I.; Elario, R.; Emeran, W.; Sealfon, S.C.; Millar, R.P. Identification of N-glycosylation sites in the gonadotropin-releasing hormone receptor: role in receptor expression but not ligand binding. Mol. Cell. Endocrinol., 1995, 107(2), 241-245.
[http://dx.doi.org/10.1016/0303-7207(94)03449-4] [PMID: 7768336]
[87]
Maione, L.; Fevre, A.; Nettore, I.C.; Manilall, A.; Francou, B.; Trabado, S.; Bouligand, J.; Guiochon-Mantel, A.; Delemer, B.; Flanagan, C.A.; Macchia, P.E.; Millar, R.P.; Young, J. Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome. Hum. Reprod., 2018, 34(1), 137-147.
[http://dx.doi.org/10.1093/humrep/dey339]] [PMID: 30476149]
[88]
Caburet, S.; Fruchter, R.B.; Legois, B.; Fellous, M.; Shalev, S.; Veitia, R.A. A homozygous mutation of GNRHR in a familial case diagnosed with polycystic ovary syndrome. Eur. J. Endocrinol., 2017, 176(5), K9-K14.
[http://dx.doi.org/10.1530/EJE-16-0968] [PMID: 28348023]
[89]
Ballesteros, J.; Kitanovic, S.; Guarnieri, F.; Davies, P.; Fromme, B.J.; Konvicka, K.; Chi, L.; Millar, R.P.; Davidson, J.S.; Weinstein, H.; Sealfon, S.C. Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J. Biol. Chem., 1998, 273(17), 10445-10453.
[http://dx.doi.org/10.1074/jbc.273.17.10445] [PMID: 9553103]
[90]
Arora, K.K.; Chung, H.O.; Catt, K.J. Influence of a species-specific extracellular amino acid on expression and function of the human gonadotropin-releasing hormone receptor. Mol. Endocrinol., 1999, 13(6), 890-896.
[http://dx.doi.org/10.1210/mend.13.6.0291] [PMID: 10379888]
[91]
de Roux, N.; Young, J.; Misrahi, M.; Schaison, G.; Milgrom, E. Loss of function mutations of the GnRH receptor: a new cause of hypogonadotropic hypogonadism. J. Pediatr. Endocrinol. Metab., 1999, 12(Suppl. 1), 267-275.
[PMID: 10698591]
[92]
Lu, Z.L.; Gallagher, R.; Sellar, R.; Coetsee, M.; Millar, R.P. Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations. J. Biol. Chem., 2005, 280(33), 29796-29803.
[http://dx.doi.org/10.1074/jbc.M413520200] [PMID: 15967801]
[93]
Betz, S.F.; Reinhart, G.J.; Lio, F.M.; Chen, C.; Struthers, R.S. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J. Med. Chem., 2006, 49(2), 637-647.
[http://dx.doi.org/10.1021/jm0506928] [PMID: 16420049]
[94]
Hövelmann, S.; Hoffmann, S.H.; Kühne, R.; ter Laak, T.; Reiländer, H.; Beckers, T. Impact of aromatic residues within transmembrane helix 6 of the human gonadotropin-releasing hormone receptor upon agonist and antagonist binding. Biochemistry, 2002, 41(4), 1129-1136.
[http://dx.doi.org/10.1021/bi0113162] [PMID: 11802711]
[95]
Fromme, B.J.; Katz, A.A.; Roeske, R.W.; Millar, R.P.; Flanagan, C.A. Role of aspartate7.32(302) of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation. Mol. Pharmacol., 2001, 60(6), 1280-1287.
[http://dx.doi.org/10.1124/mol.60.6.1280] [PMID: 11723235]
[96]
Fromme, B.J.; Katz, A.A.; Millar, R.P.; Flanagan, C.A. Pro7.33(303) of the human GnRH receptor regulates selective binding of mammalian GnRH. Mol. Cell. Endocrinol., 2004, 219(1-2), 47-59.
[http://dx.doi.org/10.1016/j.mce.2004.01.009] [PMID: 15149726]
[97]
Gonçalves, C.I.; Aragüés, J.M.; Bastos, M.; Barros, L.; Vicente, N.; Carvalho, D.; Lemos, M.C. GNRHR biallelic and digenic mutations in patients with normosmic congenital hypogonadotropic hypogonadism. Endocr. Connect., 2017, 6(6), 360-366.
[http://dx.doi.org/10.1530/EC-17-0104] [PMID: 28611058]
[98]
Davidson, J.S.; McArdle, C.A.; Davies, P.; Elario, R.; Flanagan, C.A.; Millar, R.P. Asn102 of the gonadotropin-releasing hormone receptor is a critical determinant of potency for agonists containing C-terminal glycinamide. J. Biol. Chem., 1996, 271(26), 15510-15514.
[http://dx.doi.org/10.1074/jbc.271.26.15510] [PMID: 8663086]
[99]
Standfuss, J.; Edwards, P.C.; D’Antona, A.; Fransen, M.; Xie, G.; Oprian, D.D.; Schertler, G.F. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature, 2011, 471(7340), 656-660.
[http://dx.doi.org/10.1038/nature09795] [PMID: 21389983]
[100]
Pardo, L.; Deupi, X.; Dölker, N.; López-Rodríguez, M.L.; Campillo, M. The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. ChemBioChem, 2007, 8(1), 19-24.
[http://dx.doi.org/10.1002/cbic.200600429] [PMID: 17173267]
[101]
Busby, E.R.; Sherwood, N.M. Gonadotropin-releasing hormone receptor (Gnrhr) gene knock out: normal growth and development of sensory, motor and spatial orientation behavior but altered metabolism in neonatal and prepubertal mice. PLoS One, 2017, 12(3),e0174452.
[http://dx.doi.org/10.1371/journal.pone.0174452] [PMID: 28346489]
[102]
Clarkson, J.; Busby, E.R.; Kirilov, M.; Schütz, G.; Sherwood, N.M.; Herbison, A.E. Sexual differentiation of the brain requires perinatal kisspeptin-GnRH neuron signaling. J. Neurosci., 2014, 34(46), 15297-15305.
[http://dx.doi.org/10.1523/JNEUROSCI.3061-14.2014] [PMID: 25392497]
[103]
Wu, S.; Wilson, M.D.; Busby, E.R.; Isaac, E.R.; Sherwood, N.M. Disruption of the single copy gonadotropin-releasing hormone receptor in mice by gene trap: severe reduction of reproductive organs and functions in developing and adult mice. Endocrinology, 2010, 151(3), 1142-1152.
[http://dx.doi.org/10.1210/en.2009-0598] [PMID: 20068010]
[104]
Evans, M.C.; Anderson, G.M. Neuroendocrine integration of nutritional signals on reproduction. J. Mol. Endocrinol., 2017, 58(2), R107-R128.
[http://dx.doi.org/10.1530/JME-16-0212] [PMID: 28057770]
[105]
Louis, G.W.; Greenwald-Yarnell, M.; Phillips, R.; Coolen, L.M.; Lehman, M.N.; Myers, M.G., Jr Molecular mapping of the neural pathways linking leptin to the neuroendocrine reproductive axis. Endocrinology, 2011, 152(6), 2302-2310.
[http://dx.doi.org/10.1210/en.2011-0096] [PMID: 21427219]
[106]
Schally, A.V.; Arimura, A.; Baba, Y.; Nair, R.M.; Matsuo, H.; Redding, T.W.; Debeljuk, L. Isolation and properties of the FSH and LH-releasing hormone. Biochem. Biophys. Res. Commun., 1971, 43(2), 393-399.
[http://dx.doi.org/10.1016/0006-291X(71)90766-2] [PMID: 4930860]
[107]
Matsuo, H.; Baba, Y.; Nair, R.M.; Arimura, A.; Schally, A.V. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem. Biophys. Res. Commun., 1971, 43(6), 1334-1339.
[http://dx.doi.org/10.1016/S0006-291X(71)80019-0] [PMID: 4936338]
[108]
Karten, M.J.; Rivier, J.E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr. Rev., 1986, 7(1), 44-66.
[http://dx.doi.org/10.1210/edrv-7-1-44] [PMID: 2420580]
[109]
Sealfon, S.C.; Weinstein, H.; Millar, R.P. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev., 1997, 18(2), 180-205.
[http://dx.doi.org/10.1210/edrv.18.2.0295] [PMID: 9101136]
[110]
Engel, J.B.; Schally, A.V.; Dietl, J.; Rieger, L.; Hönig, A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol. Pharm., 2007, 4(5), 652-658.
[http://dx.doi.org/10.1021/mp0700514] [PMID: 17705441]
[111]
McLeod, D.; Zinner, N.; Tomera, K.; Gleason, D.; Fotheringham, N.; Campion, M.; Garnick, M.B. Abarelix Study Group A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology, 2001, 58(5), 756-761.
[http://dx.doi.org/10.1016/S0090-4295(01)01342-5] [PMID: 11711355]
[112]
Klotz, L. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer. Expert Opin. Drug Metab. Toxicol., 2015, 11(11), 1795-1802.
[http://dx.doi.org/10.1517/17425255.2015.1085506] [PMID: 26513436]
[113]
Gentilucci, L.; Tolomelli, A.; Squassabia, F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr. Med. Chem., 2006, 13(20), 2449-2466.
[http://dx.doi.org/10.2174/092986706777935041] [PMID: 16918365]
[114]
Fàbregues, F.; Solernou, R.; Ferreri, J.; Guimerá, M.; Peralta, S.; Casals, G.; Peñarrubia, J.; Creus, M.; Manau, D. Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders. JBRA Assist. Reprod., 2019, 23(2), 130-136.
[http://dx.doi.org/10.5935/1518-0557.20180090] [PMID: 30614665]
[115]
El Hachem, H.; Sonigo, C.; Benard, J.; Presse, M.; Sifer, C.; Sermondade, N.; Grynberg, M. Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation. PLoS One, 2018, 13(12),e0208576.
[http://dx.doi.org/10.1371/journal.pone.0208576] [PMID: 30521621]
[116]
Burnham, V.; Sundby, C.; Laman-Maharg, A.; Thornton, J. Luteinizing hormone acts at the hippocampus to dampen spatial memory. Horm. Behav., 2017, 89, 55-63.
[http://dx.doi.org/10.1016/j.yhbeh.2016.11.007] [PMID: 27847314]
[117]
Palm, R.; Chang, J.; Blair, J.; Garcia-Mesa, Y.; Lee, H.G.; Castellani, R.J.; Smith, M.A.; Zhu, X.; Casadesus, G. Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J. Neurochem., 2014, 130(1), 115-125.
[http://dx.doi.org/10.1111/jnc.12706] [PMID: 24601954]
[118]
Bowen, R.L.; Butler, T.; Atwood, C.S. Not all androgen deprivation therapies are created equal: leuprolide and the decreased risk of developing Alzheimer’s disease. J. Clin. Oncol., 2016, 34(23), 2800.
[http://dx.doi.org/10.1200/JCO.2015.66.3997] [PMID: 27298416]
[119]
Fujino, M.; Kobayashi, S.; Obayashi, M.; Fukuda, T.; Shinagawa, S. Synthesis and biological activities of analogs of luteinizing hormone releasing hormone (LH-RH). Biochem. Biophys. Res. Commun., 1972, 49(3), 698-705.
[http://dx.doi.org/10.1016/0006-291X(72)90467-6] [PMID: 4565126]
[120]
Raivio, T.; Falardeau, J.; Dwyer, A.; Quinton, R.; Hayes, F.J.; Hughes, V.A.; Cole, L.W.; Pearce, S.H.; Lee, H.; Boepple, P.; Crowley, W.F., Jr; Pitteloud, N. Reversal of idiopathic hypogonadotropic hypogonadism. N. Engl. J. Med., 2007, 357(9), 863-873.
[http://dx.doi.org/10.1056/NEJMoa066494] [PMID: 17761590]
[121]
Casper, R.F. Introduction: Gonadotropin-releasing hormone agonist triggering of final follicular maturation for in vitro fertilization. Fertil. Steril., 2015, 103(4), 865-866.
[http://dx.doi.org/10.1016/j.fertnstert.2015.01.012] [PMID: 25681856]
[122]
van der Linden, M.; Buckingham, K.; Farquhar, C.; Kremer, J.A.; Metwally, M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev., 2015, 2015(7),CD009154.
[http://dx.doi.org/10.1002/14651858.CD009154.pub3] [PMID: 26148507]
[123]
Engmann, L.L.; Maslow, B.S.; Kaye, L.A.; Griffin, D.W.; DiLuigi, A.J.; Schmidt, D.W.; Grow, D.R.; Nulsen, J.C.; Benadiva, C.A. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial. J. Ovarian Res., 2019, 12(1), 8.
[http://dx.doi.org/10.1186/s13048-019-0483-7] [PMID: 30684970]
[124]
Platteeuw, L.; D’Hooghe, T. Novel agents for the medical treatment of endometriosis. Curr. Opin. Obstet. Gynecol., 2014, 26(4), 243-252.
[http://dx.doi.org/10.1097/GCO.0000000000000084] [PMID: 24978852]
[125]
Gründker, C.; Günthert, A.R.; Hellriegel, M.; Emons, G. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur. J. Endocrinol., 2004, 151(5), 619-628.
[http://dx.doi.org/10.1530/eje.0.1510619] [PMID: 15538941]
[126]
Fister, S.; Günthert, A.R.; Aicher, B.; Paulini, K.W.; Emons, G.; Gründker, C. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res., 2009, 69(16), 6473-6481.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4657] [PMID: 19638591]
[127]
Labrie, F. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. Endocr. Relat. Cancer, 2014, 21(4), R301-R317.
[http://dx.doi.org/10.1530/ERC-13-0165] [PMID: 24825748]
[128]
Kittai, A.S.; Blank, J.; Graff, J.N. Gonadotropin-releasing hormone antagonists in prostate cancer. Oncology (Williston Park), 2018, 32(12), 599-602, 604-606.
[PMID: 30632129]
[129]
Crawford, E.D.; Tombal, B.; Keane, T.; Boccardo, F.; Miller, K.; Shore, N.; Moul, J.W.; Damber, J.E.; Collette, L.; Persson, B.E. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand. J. Urol., 2018, 52(5-6), 349-357.
[http://dx.doi.org/10.1080/21681805.2018.1522372]] [PMID: 30624128]
[130]
Rick, F.G.; Block, N.L.; Schally, A.V. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin. Pharmacother., 2013, 14(16), 2237-2247.
[http://dx.doi.org/10.1517/14656566.2013.834328] [PMID: 23984804]
[131]
Cardozo, E.R.; Thomson, A.P.; Karmon, A.E.; Dickinson, K.A.; Wright, D.L.; Sabatini, M.E. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J. Assist. Reprod. Genet., 2015, 32(4), 587-596.
[http://dx.doi.org/10.1007/s10815-015-0428-z] [PMID: 25595540]
[132]
Tan, O.; Bukulmez, O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr. Opin. Obstet. Gynecol., 2011, 23(4), 238-244.
[http://dx.doi.org/10.1097/GCO.0b013e328348a3ce] [PMID: 21666463]
[133]
Pappa, E.V.; Zompra, A.A.; Spyranti, Z.; Diamantopoulou, Z.; Pairas, G.; Lamari, F.N.; Katsoris, P.; Spyroulias, G.A.; Cordopatis, P. Enzymatic stability, solution structure and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs. Biopolymers, 2011, 96(3), 260-272.
[http://dx.doi.org/10.1002/bip.21521] [PMID: 20632397]
[134]
Shao, W.M.; Bai, W.J.; Chen, Y.M.; Liu, L.; Wang, Y.J. Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review. Beijing Da Xue Xue Bao Yi Xue Ban,, 2014, 46(4), 642-645.
[PMID: 25131486]
[135]
Letassy, N.A.; Thompson, D.F.; Britton, M.L.; Suda, R.R., Sr Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis. DICP, 1990, 24(12), 1204-1209.
[http://dx.doi.org/10.1177/106002809002401212] [PMID: 2151003]
[136]
Shore, N.; Cookson, M.S.; Gittelman, M.C. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int., 2012, 109(2), 226-232.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10370.x] [PMID: 21851539]
[137]
Lewis, K.A.; Eugster, E.A. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty. Drug Des. Devel. Ther., 2009, 3, 1-5.
[PMID: 19920916]
[138]
Lahlou, N.; Carel, J.C.; Chaussain, J.L.; Roger, M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J. Pediatr. Endocrinol. Metab., 2000, 13(Suppl. 1), 723-737.
[http://dx.doi.org/10.1515/JPEM.2000.13.S1.723] [PMID: 10969915]
[139]
de Voogt, H.J.; Adenauer, H.; Widdra, W.G. The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents. Scand. J. Urol. Nephrol. Suppl., 1991, 138, 131-136.
[PMID: 1838426]
[140]
Jonat, W.; Kaufmann, M.; Sauerbrei, W.; Blamey, R.; Cuzick, J.; Namer, M.; Fogelman, I.; de Haes, J.C.; de Matteis, A.; Stewart, A.; Eiermann, W.; Szakolczai, I.; Palmer, M.; Schumacher, M.; Geberth, M.; Lisboa, B. Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J. Clin. Oncol., 2002, 20(24), 4628-4635.
[http://dx.doi.org/10.1200/JCO.2002.05.042] [PMID: 12488406]
[141]
Lin, Y.H.; Wen, Y.R.; Chang, Y.; Seow, K.M.; Hsieh, B.C.; Hwang, J.L.; Tzeng, C.R. Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study. Fertil. Steril., 2010, 94(1), 179-183.
[http://dx.doi.org/10.1016/j.fertnstert.2009.02.062] [PMID: 19339001]
[142]
Steinberg, M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin. Ther., 2009, 31(Pt 2), 2312-2331.
[http://dx.doi.org/10.1016/j.clinthera.2009.11.009] [PMID: 20110043]
[143]
Royster, G.D.; Retzloff, M.G.; Robinson, R.D.; King, J.A.; Propst, A.M. Effect of length of controlled ovarian hyperstimulation using a gonadotropin-releasing hormone antagonist on in vitro fertilization pregnancy rates. J. Reprod. Med., 2012, 57(9-10), 415-420.
[PMID: 23091989]
[144]
Verschraegen, C.F.; Westphalen, S.; Hu, W.; Loyer, E.; Kudelka, A.; Völker, P.; Kavanagh, J.; Steger, M.; Schulz, K.D.; Emons, G. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol. Oncol., 2003, 90(3), 552-559.
[http://dx.doi.org/10.1016/S0090-8258(03)00408-6] [PMID: 13678723]
[145]
Hosseini, S.A.; Rajabi, F.; Akbari Sari, A.; Ayati, M.; Heidari, S.; Ghamary, F. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Med. J. Islam. Repub. Iran, 2016, 30, 317.
[PMID: 27390687]
[146]
Rick, F.G.; Schally, A.V. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol. Oncol., 2015, 33(6), 270-274.
[http://dx.doi.org/10.1016/j.urolonc.2014.11.006] [PMID: 25512159]
[147]
Albertsen, P.C.; Klotz, L.; Tombal, B.; Grady, J.; Olesen, T.K.; Nilsson, J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur. Urol., 2014, 65(3), 565-573.
[http://dx.doi.org/10.1016/j.eururo.2013.10.032] [PMID: 24210090]
[148]
Engel, J.B.; Schally, A.V.; Buchholz, S.; Seitz, S.; Emons, G.; Ortmann, O. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch. Gynecol. Obstet., 2012, 286(2), 437-442.
[http://dx.doi.org/10.1007/s00404-012-2335-1] [PMID: 22555802]
[149]
Emons, G.; Gorchev, G.; Sehouli, J.; Wimberger, P.; Stähle, A.; Hanker, L.; Hilpert, F.; Sindermann, H.; Gründker, C.; Harter, P. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). Gynecol. Oncol., 2014, 133(3), 427-432.
[http://dx.doi.org/10.1016/j.ygyno.2014.03.576] [PMID: 24713545]
[150]
Günthert, A.R.; Gründker, C.; Bongertz, T.; Nagy, A.; Schally, A.V.; Emons, G. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Res. Treat., 2004, 87(3), 255-264.
[http://dx.doi.org/10.1007/s10549-004-8806-8] [PMID: 15528968]
[151]
Miwa, K.; Hitaka, T.; Imada, T.; Sasaki, S.; Yoshimatsu, M.; Kusaka, M.; Tanaka, A.; Nakata, D.; Furuya, S.; Endo, S.; Hamamura, K.; Kitazaki, T. Discovery of 1-4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J. Med. Chem., 2011, 54, 4998-5012.
[http://dx.doi.org/10.1021/jm200216q] [PMID: 21657270]
[152]
Tukun, F.L.; Olberg, D.E.; Riss, P.J.; Haraldsen, I.; Kaass, A.; Klaveness, J. Recent development of non-peptide GnRH antagonists. Molecules, 2017, 22(12), 22.
[http://dx.doi.org/10.3390/molecules22122188] [PMID: 29232843]
[153]
Dmowski, W.P. Danazol. A synthetic steroid with diverse biologic effects. J. Reprod. Med., 1990, 35(1)(Suppl.), 69-74.
[PMID: 2404115]
[154]
Fedele, L.; Bianchi, S.; Viezzoli, T.; Arcaini, L.; Candiani, G.B. Gestrinone versus danazol in the treatment of endometriosis. Fertil. Steril., 1989, 51(5), 781-785.
[http://dx.doi.org/10.1016/S0015-0282(16)60666-0] [PMID: 2523321]
[155]
Chen, C.; Wu, D.; Guo, Z.; Xie, Q.; Reinhart, G.J.; Madan, A.; Wen, J.; Chen, T.; Huang, C.Q.; Chen, M.; Chen, Y.; Tucci, F.C.; Rowbottom, M.; Pontillo, J.; Zhu, Y.F.; Wade, W.; Saunders, J.; Bozigian, H.; Struthers, R.S. Discovery of sodium R-(+)-4-2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4 -methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylaminobutyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J. Med. Chem., 2008, 51, 7478-7485.
[http://dx.doi.org/10.1021/jm8006454] [PMID: 19006286]
[156]
Hara, T.; Araki, H.; Kusaka, M.; Harada, M.; Cho, N.; Suzuki, N.; Furuya, S.; Fujino, M. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J. Clin. Endocrinol. Metab., 2003, 88(4), 1697-1704.
[http://dx.doi.org/10.1210/jc.2002-021065] [PMID: 12679460]
[157]
Alessandro, P.; Luigi, N.; Felice, S.; Maria, P.A.; Benedetto, M.G.; Stefano, A. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature. Arch. Gynecol. Obstet., 2017, 295(4), 827-832.
[http://dx.doi.org/10.1007/s00404-017-4328-6] [PMID: 28255765]
[158]
Sasaki, S.; Cho, N.; Nara, Y.; Harada, M.; Endo, S.; Suzuki, N.; Furuya, S.; Fujino, M. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. J. Med. Chem., 2003, 46(1), 113-124.
[http://dx.doi.org/10.1021/jm020180i] [PMID: 12502365]
[159]
Boyce, M.; Clark, E.; Johnston, A.; George, M.; Davies, J.; Hibberd, M. Effects of single and repeated oral doses of TAK-013, a new non-peptide gonadotropin-releasing hormone (GnRH) antagonist, in healthy post-menopausal women. Fertil. Steril., 2002, 78, S281-S282.
[http://dx.doi.org/10.1016/S0015-0282(02)03947-X]
[160]
MacLean, D.B.; Shi, H.; Faessel, H.M.; Saad, F. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males. J. Clin. Endocrinol. Metab., 2015, 100(12), 4579-4587.
[http://dx.doi.org/10.1210/jc.2015-2770] [PMID: 26502357]

Rights & Permissions Print Cite
Article Metrics
194
14
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy